173 related articles for article (PubMed ID: 37414979)
21. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Sonbol MB; Benkhadra R; Wang Z; Firwana B; Walden DJ; Mody K; Hubbard JM; Murad MH; Ahn DH; Bekaii-Saab T
Oncologist; 2019 Sep; 24(9):1174-1179. PubMed ID: 31164455
[TBL] [Abstract][Full Text] [Related]
22. Impact of KRAS
Tabernero J; Taieb J; Fakih M; Prager GW; Van Cutsem E; Ciardiello F; Mayer RJ; Amellal N; Skanji D; Calleja E; Yoshino T
ESMO Open; 2024 Mar; 9(3):102945. PubMed ID: 38471240
[TBL] [Abstract][Full Text] [Related]
23. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
24. Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy.
Matsuoka S; Fujii H; Iihara H; Ohata K; Hirose C; Watanabe D; Sadaka S; Kiyama S; Makiyama A; Takahashi T; Kobayashi R; Matsuhashi N; Suzuki A
Anticancer Res; 2023 May; 43(5):2351-2357. PubMed ID: 37097664
[TBL] [Abstract][Full Text] [Related]
25. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
[No Abstract] [Full Text] [Related]
26. A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
Miyamoto Y; Lenz HJ; Baba H
Expert Rev Clin Pharmacol; 2016; 9(3):355-65. PubMed ID: 26677869
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Fujii H; Matsuhashi N; Kitahora M; Takahashi T; Hirose C; Iihara H; Yamada Y; Watanabe D; Ishihara T; Suzuki A; Yoshida K
Oncologist; 2020 Mar; 25(3):e469-e476. PubMed ID: 32162797
[TBL] [Abstract][Full Text] [Related]
28. Integrated safety summary for trifluridine/tipiracil (TAS-102).
Falcone A; Ohtsu A; Van Cutsem E; Mayer RJ; Buscaglia M; Bendell JC; Kopetz S; Bebeau P; Yoshino T
Anticancer Drugs; 2018 Jan; 29(1):89-96. PubMed ID: 29176395
[TBL] [Abstract][Full Text] [Related]
29. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
van de Haar J; Ma X; Ooft SN; van der Helm PW; Hoes LR; Mainardi S; Pinato DJ; Sun K; Salvatore L; Tortora G; Zurlo IV; Leo S; Giampieri R; Berardi R; Gelsomino F; Merz V; Mazzuca F; Antonuzzo L; Rosati G; Stavraka C; Ross P; Rodriquenz MG; Pavarana M; Messina C; Iveson T; Zoratto F; Thomas A; Fenocchio E; Ratti M; Depetris I; Cergnul M; Morelli C; Libertini M; Parisi A; De Tursi M; Zanaletti N; Garrone O; Graham J; Longarini R; Gobba SM; Petrillo A; Tamburini E; La Verde N; Petrelli F; Ricci V; Wessels LFA; Ghidini M; Cortellini A; Voest EE; Valeri N
Nat Med; 2023 Mar; 29(3):605-614. PubMed ID: 36864254
[TBL] [Abstract][Full Text] [Related]
30. Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
Cremolini C; Rossini D; Martinelli E; Pietrantonio F; Lonardi S; Noventa S; Tamburini E; Frassineti GL; Mosconi S; Nichetti F; Murgioni S; Troiani T; Borelli B; Zucchelli G; Dal Maso A; Sforza V; Masi G; Antoniotti C; Di Bartolomeo M; Miceli R; Ciardiello F; Falcone A
Oncologist; 2018 Oct; 23(10):1178-1187. PubMed ID: 29739893
[TBL] [Abstract][Full Text] [Related]
31. Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).
Satake H; Kato T; Oba K; Kotaka M; Kagawa Y; Yasui H; Nakamura M; Watanabe T; Matsumoto T; Kii T; Terazawa T; Makiyama A; Takano N; Yokota M; Okita Y; Matoba K; Hasegawa H; Tsuji A; Komatsu Y; Yoshino T; Yamazaki K; Mishima H; Oki E; Nagata N; Sakamoto J
Oncologist; 2020 Dec; 25(12):e1855-e1863. PubMed ID: 32666647
[TBL] [Abstract][Full Text] [Related]
32. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Dadduzio V; Salvatore L; Borelli B; Pietrantonio F; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ
Eur J Cancer; 2017 Nov; 86():197-206. PubMed ID: 28992563
[TBL] [Abstract][Full Text] [Related]
33. Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors.
Stavraka C; Pouptsis A; Synowiec A; Angelis V; Satterthwaite L; Khan S; Chauhan M; Holden C; Young S; Karampera C; Martinou M; Mills-Baldock T; Baxter M; Barry A; Eccles B; Iveson T; Shiu KK; Hill M; Abdel-Raouf S; Graham JS; Thomas A; Ross PJ
Clin Colorectal Cancer; 2021 Dec; 20(4):342-349. PubMed ID: 34696965
[TBL] [Abstract][Full Text] [Related]
34. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis.
Gao L; Tang L; Hu Z; Peng J; Li X; Liu B
Front Oncol; 2023; 13():1269203. PubMed ID: 37810981
[TBL] [Abstract][Full Text] [Related]
36. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
[TBL] [Abstract][Full Text] [Related]
37. Comparison of efficacy and safety for patients with beyond second line treated metastatic colorectal cancer: a network meta-analysis of randomized controlled trials.
Cao M; Zhou M; Zhang J
J Chemother; 2020 Jul; 32(4):163-170. PubMed ID: 32081104
[TBL] [Abstract][Full Text] [Related]
38. Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Giuliani J
Clin Colorectal Cancer; 2022 Jun; 21(2):e145-e147. PubMed ID: 34969632
[TBL] [Abstract][Full Text] [Related]
39. Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data.
Vitale P; Zanaletti N; Famiglietti V; De Falco V; Cervantes A; Rosellò S; Fenocchio E; Milanesio M; Lombardi P; Ciardiello D; Martini G; Martinelli E; Ciardiello F; Troiani T; Napolitano S
Clin Colorectal Cancer; 2021 Sep; 20(3):227-235. PubMed ID: 34226142
[TBL] [Abstract][Full Text] [Related]
40. Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
Shiroyama M; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Shimada Y; Esaki T; Makiyama A; Moriwaki T
Sci Rep; 2023 Oct; 13(1):17931. PubMed ID: 37863951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]